title: [Cyclosporin treatment of interstitial pneumonia and monitoring of serum concentration].
abstract: Recently, cyclosporin has been reported to be a promising drug for the treatment of interstitial pneumonia. Monitoring of the serum cyclosporin concentration is important for the safety and efficacy of treatment. We measured the concentrations of this drug just before (C0) and 2 hours after (C2) administration, and the area under the concentration-time curve from the start of administration for 5 hours (AUC 0-5) in 58 patients. We found that C2 has the strongest correlation with AUC 0-5, which indicates the efficacy of cyclosporin. In 11 cases of interstitial pneumonia, 5 showed deterioration despite cyclosporin treatment. Three of those 5 cases had low C2 and AUC 0-5 levels, indicating that they were low absorbers and slow absorbers, which may be associated with a poor response. Therefore, the monitoring of the cyclosporin concentration is important especially in progressive cases of interstitial pneumonia that deteriorate despite cyclosporin treatment.
authors.affiliation: Second Department of Medicine, Hamamatsu University School of Medicine.
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Enomoto
authors.forename: Takafumi
authors.initials: T
authors.lastname: Suda
authors.forename: Dai
authors.initials: D
authors.lastname: Hashimoto
authors.forename: Tateaki
authors.initials: T
authors.lastname: Naito
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Fujisawa
authors.forename: Seiichi
authors.initials: S
authors.lastname: Miwa
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakano
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Suzuki
authors.forename: Koshi
authors.initials: K
authors.lastname: Yokomura
authors.forename: Kyotaro
authors.initials: K
authors.lastname: Ide
authors.forename: Kingo
authors.initials: K
authors.lastname: Chida
mesh_terms: D000368:Aged; D019540:Area Under Curve; D016572:Cyclosporine / Q000097:blood* / Q000627:therapeutic use*; D003882:Dermatomyositis / Q000150:complications; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood* / Q000627:therapeutic use*; D017563:Lung Diseases, Interstitial / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000150:complications
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine